Twitter

Link your Twitter Account to Market Wire News


When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.


Be alerted of any news about your stocks and see what other stocks are trending.


home / news releases / MNMD - Mind Medicine Advanced Clinical Trials for its 3 Lead Drug Candidates in Q1

MNMD - Mind Medicine Advanced Clinical Trials for its 3 Lead Drug Candidates in Q1

Mind Medicine (MindMed) Inc.

Mind Medicine Inc. (NASDAQ: MNMD) (NEO: MMED) announced Monday its financial results for the first quarter of 2022. MindMed is a New York-based psychedelic medicine biotechnology company that develops psychedelic-inspired drugs and therapies to combat addiction and mental illness.

MindMed Had Higher Expenses in Q1

As of March 31, 2022, MindMed had cash on hand totaling $120.5 million, compared to $133.5 million as of December 31, 2021. MindMed believes that its available cash will be sufficient to meet its operational needs beyond its main stages of development in 2023 and until 2024.

Net cash ...

Get early insight on hidden secret gems on StockStreetNews . Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here .

All content provided by StockStreetNews is subject to our Terms Of Use and Disclaimer .

For further details see:

Mind Medicine Advanced Clinical Trials for its 3 Lead Drug Candidates in Q1
Stock Information
Company Name: Mind Medicine (MindMed) Inc.
Stock Symbol: MNMD
Market: NASDAQ
Website: mindmed.co
Menu
MNMD MNMD Quote MNMD Short MNMD News MNMD Articles MNMD Message Board
Get MNMD Alerts

News, Short Squeeze, Breakout and More Instantly...